Healthcare / Drug Manufacturers - GeneralKOSDAQ
$7010.00
-390.00 (-5.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $3.0B · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$37.1B
P/E
8.7x
↓EV/EBITDA
7.4x
↓ROE
10.0%
↑Gross Margin
27.2%
↓Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.6%
FCF CAGR
—
FCF margin
-33.0%
FCF / Net income
-2.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $27.62B · net income $4.27B · FCF $-9.10B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $27.62B | $27.62B | $27.52B | $30.05B | $25.59B |
| Net Income | $4.27B | $4.27B | $3.72B | $4.69B | $3.46B |
| EBITDA | $5.90B | $5.90B | $5.15B | $6.81B | $5.33B |
| EPS | 808.00 | 808.00 | 803.00 | 1101.00 | 811.00 |
| Gross Margin | 27.2% | 27.2% | 28.1% | 26.4% | 24.1% |
| Operating Margin | 13.6% | 13.6% | 13.6% | 16.7% | 14.8% |
| Net Margin | 15.5% | 15.5% | 13.5% | 15.6% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.18 | 0.31 | 0.38 |
| Current Ratio | 2.09 | 2.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.10B | $-9.10B | $3.21B | $3.02B | $2.31B |
| Returns | |||||
| ROE | 10.0% | 10.0% | 9.7% | 20.4% | 18.9% |
| Valuation | |||||
| P/E | 8.68 | 8.68 | 17.86 | — | — |
| EV/EBITDA | 7.39 | 7.39 | 13.33 | — | — |
| P/B | 0.87 | 0.87 | 1.72 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 0.4% | 0.4% | -8.4% | 17.4% | — |
| EPS Growth | 0.6% | 0.6% | -27.1% | 35.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-8.4%
EPS terminal req.
$622.02
Spread vs growth
9.0%
5Y implied EPS CAGR
-1.4%
EPS terminal req.
$752.65
Spread vs growth
2.0%
10Y implied EPS CAGR
4.1%
EPS terminal req.
$1212.14
Spread vs growth
-3.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.2%
Start / end P/E
14.6x → 8.7x
EPS bridge
803.00 → 808.00
Residual
-0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.